ReviewNano reviews & experiments2017
Possible role of nanocarriers in drug delivery against cervical cancer.
Review in Nano reviews & experiments, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 72 citations in OpenAlex.
- Topoisomerase inhibitors in cervical cancer: mechanistic insights and therapeutic strategies.Molecular medicine (Cambridge, Mass.) · 2026Review
- Arthropod venom peptides: Pioneering nanotechnology in cancer treatment and drug delivery.Cancer pathogenesis and therapy · 2026Review
- Nanomedicines for the treatment of genitourinary neoplasms.Materials today. Bio · 2025Review
- Mapping research hotspots and trends in hepatocellular carcinoma nanomedicine: a bibliometric analysis.Discover oncology · 2025Article
- Molecular interaction of human papilloma virus (HPV) with microRANs: insights into the development of cervical cancer and treatment approaches.Infectious agents and cancer · 2025Review
- Article
- Investigating new drugs from marine seaweed metabolites for cervical cancer therapy by molecular dynamic modeling approach.Scientific reports · 2025Article
- Nanotechnology and nanobots unleashed: pioneering a new era in gynecological cancer management - a comprehensive review.Cancer chemotherapy and pharmacology · 2025Review
- The Know-how of Polymeric Nanocarrier Based Vaginal Drug Delivery System: Pitfalls, Challenges and Trends.Pharmaceutical nanotechnology · 2025Review
- Novel Drug Delivery Approaches for the Localized Treatment of Cervical Cancer.AAPS PharmSciTech · 2024Review
- Gold-Enhanced Brachytherapy by a Nanoparticle-Releasing Hydrogel and 3D-Printed Subcutaneous Radioactive Implant Approach.Advanced healthcare materials · 2023Article
- Unveiling the multitargeted repurposing potential of taxifolin (dihydroquercetin) in cervical cancer: an extensive MM\GBSA-based screening, and MD simulation study.Medical oncology (Northwood, London, England) · 2023Article
- Review
- Update on the Use of Nanocarriers and Drug Delivery Systems and Future Directions in Cervical Cancer.Journal of immunology research · 2022Review
- Current Advances inFrontiers in pharmacology · 2021Review
- Cervical cancer: a meta-analysis, therapy and future of nanomedicine.Ecancermedicalscience · 2020Review
- Zeolitic Imidazolate Framework-8 as pH-Sensitive Nanocarrier for "Arsenic Trioxide" Drug Delivery.Chemistry (Weinheim an der Bergstrasse, Germany) · 2019Article
- Efficacy of Surface-Modified PLGA Nanoparticles as a Function of Cervical Cancer Type.Pharmaceutical research · 2019Article
- In situ-forming and pH-responsive hydrogel based on chitosan for vaginal delivery of therapeutic agents.Journal of materials science. Materials in medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.